Table 3.
Adverse effects included in our meta-analysis
| Study/Trial name | Treat ment/Contr ol group | Thromb ocytop enia | Anemia | Neutrop enia | Lymph openia | URTI* | Diarr hea | Fatigu e | Dyspn ea | Pneum onia |
|---|---|---|---|---|---|---|---|---|---|---|
| Dimopoulos et al./CANDOR trial | Treat ment group | 115 (36.8%) | 101 (32.3%) | 43 (13.8 %) | 27 (8.6 %) | 90 (2 8.9 %) | 97 (31 0.1%) | 75 (24 %) | 61 (19.5%) | 55 (17.3 %) |
| Contr ol group | 45 (29%) | 48 (31.2 %) | 15 (9.7%) | 12 (8%) | 35 (2 2.8 %) | 22 (14 0.3%) | 28 (18.2%) | 34 (22.1%) | 19 (12.4 %) | |
| Spencer, et al./CASTOR trial | Treat ment group | 145 (57.7%) | 69 (27.5 %) | 46 (18.3 %) | 32 (12.7 %) | 76 (3 0.3 %) | 85 (33 0.9%) | 53 (21.1%) | 46 (18.3%) | 36 (14.3 %) |
| Contr ol group | 105 (42.5%) | 75 (30.4 %) | 23 (9.3%) | 9 (3.6%) | 43 (1 7.4 %) | 53 (21 0.5%) | 58 (23.5%) | 21 (8.5 %) | 31 (12.6 %) | |
| Dimopoulos, et al./POLLUX trial | Treat ment group | 81 (28.3 %) | 104 (36.4%) | 172 (60.1 %) | 18 (6.3 %) | 105 (36.7 %) | 144 (5 0.3%) | 103 (3 6%) | 59 (20.7%) | 58 (20.3 %) |
| Contr ol group | 87 (30.7 %) | 109 (38.5%) | 127 (44.8 %) | 16 (5.6 %) | 74 (2 6.2 %) | 89 (31 0.5%) | 85 (30 %) | 35 (12.4%) | 42 (14.8 %) |
*URTI=Upper respiratory tract infection